Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ROCHE's ROFERON-A EFFICACY IN CHRONIC MYELOGENOUS LEUKEMIA

Executive Summary

ROCHE's ROFERON-A EFFICACY IN CHRONIC MYELOGENOUS LEUKEMIA is suggested in a study of 17 patients published in the April 24 issue of the New England Journal of Medicine. Investigators Moshe Talpaz, MD, et al, M. D. Anderson Hospital and Tumor Institute, concluded that the data, which they said are preliminary and need further confirmation, "suggest that recombinant human interferon alpha[a] is effective in inducing hematologic remission in most patients with benign-phase chronic myelogenous leukemia and in suppressing the Philadelphia chromosome in some of these patients." The investigators reported that 17 patients with Philadelphia-chromosome-positive chronic myelogenous leukemia were given daily intramuscular injections of Roferon. The starting dose was 5X10 units per square meter of body-surface. The dose was reduced by 50% if toxicity was observed and increased 100% in cases of treatment resistance or only a minor cytoreductive effect. A hematologic remission "required normalization of the peripheral blood white cell counts, to levels of less than 9X10 per microliter; normalization of the differential cell counts, with no immature forms . . . and the disappearance of all clinical symptoms and signs of disease, including palpable splenomegaly," Talpaz, et al, stated. The authors reported that "14 patients responded to the treatment, of whom 13 had a hematologic remission and one hand a partial hematologic remission. The median number of white cells in those patients declined from 60.9X10 to 3.4X10 per microliter, and the median number of platelets decreased from 476X10 to 231X10 per microliter." Further, the authors noted that "among the five responding patients who had splenomegaly before treatment, the spleen size returned to normal in four and decreased by 75% in one, although it remained enlarged," and "bone marrow cellularity declined from a median of 92.5% to a median of 57.5%." Regarding Philadelphia chromosome suppression, Talpaz, et al, stated that "in six of the patients with hematologic remission, complete suppression of Philadelphia cells was observed on at least one examination." The investigators noted that "of the 14 patients who responded, 11 have received the interferon therapy for 9 to 15 months." They said one patient relapsed during the treatment, and treatment was temporarily interrupted in two patients because of toxicity. Side effects associated with the recombinant human alpha interferon included diffuse neurologic toxicity, which the investigators said occurred in six of the patients. Two of these patients had extrapyramidal symptoms with a Parkinsonian-like syndrome, Talpaz, et al, said. Other side effects included weight loss, mild, dry cough, postnasal drip, arthralgias and myalgias, anemia, and thrombocytopenia, which developed in two patients. The investigators added that "it is notable that the severe muscle and bone pains that were observed during the administration of partially purified alpha-interferon did not occur with recombinant human interferon alpha[a]."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS010061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel